<DOC>
	<DOCNO>NCT00491244</DOCNO>
	<brief_summary>Chronic hepatitis C virus ( HCV ) infection common dialysis patient . Interferon ( IFN ) -based treatment chronic hepatitis C mainstay therapy immunocompetent patient . In dialysis patient , treatment conventional pegylated interferon also receive much attention recently . Two meta-analyses evaluate efficacy safety conventional IFN alfa monotherapy show sustained virologic response ( SVR ) rate 37 % 33 % , respectively ; correspond dropout rate 17 % 29.6 % , respectively.The efficacy safety pegylated IFN alfa-2a 2b treat dialysis patient show conflict result , favorable outcome patient treat pegylated IFN alfa-2a ( 135-180 μg/week : SVR 33-75 % , well tolerate ) treat pegylated IFN alfa-2b ( 0.5-1.0 μg/week : SVR 12.5 % , poorly tolerate . Currently , IFN-based therapy treatment HCV infection initiate dialysis stage , use IFN RT patient harbor high risk acute graft rejection , low response rate concomitant use immunosuppressive agent . Ribavirin , use combination IFN treat chronic hepatitis C general patient achieve high SVR rate IFN monotherapy , consider contraindicated dialysis patient chronic hepatitis C due risk severe hemolytic anemia . However , pilot study evaluate combined conventional IFN alfa plus low dose ribavirin ( 170-300 mg/day ) show SVR rate 17 % -66 % 24-48 week treatment . In addition , recent study include 6 patient combination pegylated IFN alfa plus low dose ribavirin also show SVR rate 50 % . In study , treatment pegylated IFN alfa-2a plus low dose ribavirin achieve high SVR rate pegylated IFN alfa-2b plus low dose ribavirin ( 100 % vs. 25 % ) . Based long-term favorable outcome dialysis patient eradicate HCV , superior response pegylated IFN alfa-2a plus low dose ribavirin pegylated IFN alfa-2b plus low dose ribavirin treat dialysis patient chronic hepatitis C , aim study evaluate efficacy safety pegylated IFN alfa-2a plus low dose ribavirin versus pegylated interferon alfa-2a alone treatment naïve dialysis patient chronic hepatitis C .</brief_summary>
	<brief_title>Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Chronic hepatitis C virus ( HCV ) infection common dialysis patient , report prevalence vary 3 % 80 % worldwide . ( 1-3 ) Although patient usually mild symptom moderate elevation alanine transaminase level , recent international collaborative survey prospective study find anti-HCV seropositivity positive HCV RNA risk factor mortality hepatocellular carcinoma ( HCC ) . ( 4-7 ) Furthermore , progressive hepatic fibrosis , poor patient graft survival observer dialysis patient HCV infection undergo renal transplantation ( RT ) , suggest immunosuppression follow RT may worsen course hepatic fibrosis renal graft function . ( 8-13 ) These line evidence indicate HCV infection dialysis population important issue tackle . Interferon ( IFN ) -based treatment chronic hepatitis C mainstay therapy immunocompetent patient . In dialysis patient , treatment conventional pegylated interferon also receive much attention recently . Two meta-analyses evaluate efficacy safety conventional IFN alfa monotherapy show sustained virologic response ( SVR ) rate 37 % 33 % , respectively ; correspond dropout rate 17 % 29.6 % , respectively . ( 14,15 ) The efficacy safety pegylated IFN alfa-2a 2b treat dialysis patient show conflict result , favorable outcome patient treat pegylated IFN alfa-2a ( 135-180 μg/week : SVR 33-75 % , well tolerate ) treat pegylated IFN alfa-2b ( 0.5-1.0 μg/week : SVR 12.5 % , poorly tolerate ) , ( 16-21 ) may result different pharmacokinetic profile two pegylated IFNs . Currently , IFN-based therapy treatment HCV infection initiate dialysis stage , use IFN RT patient harbor high risk acute graft rejection , ( 22,23 ) low response rate concomitant use immunosuppressive agent . ( 24,25 ) Ribavirin , use combination IFN treat chronic hepatitis C general patient achieve high SVR rate IFN monotherapy , consider contraindicated dialysis patient chronic hepatitis C due risk severe hemolytic anemia . However , pilot study evaluate combined conventional IFN alfa plus low dose ribavirin ( 170-300 mg/day ) show SVR rate 17 % -66 % 24-48 week treatment . ( 26-28 ) In addition , recent study include 6 patient combination pegylated IFN alfa plus low dose ribavirin also show SVR rate 50 % . ( 29 ) In study , treatment pegylated IFN alfa-2a plus low dose ribavirin achieve high SVR rate pegylated IFN alfa-2b plus low dose ribavirin ( 100 % vs. 25 % ) Based long-term favorable outcome dialysis patient eradicate HCV , superior response pegylated IFN alfa-2a plus low dose ribavirin pegylated IFN alfa-2b plus low dose ribavirin treat dialysis patient chronic hepatitis C , aim study evaluate efficacy safety pegylated IFN alfa-2a plus low dose ribavirin versus pegylated interferon alfa-2a treatment naïve dialysis patient chronic hepatitis C .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age 1865 year old Creatinine clearance ( Ccr ) &lt; 15 ml/min/1.73 m2 AntiHCV ( Abbott HCV EIA 3.0 , Abbott Diagnostic , Chicago , IL ) positive &gt; 6 month Detectable serum quantitative HCVRNA ( Cobas Taqman HCV test , version 2 , Roche Diagnostics ) dynamic range 25391000000 IU/ml Receiving interferonbased therapy chronic hepatitis C Severe anemia ( hemoglobin &lt; 10 g/dL ) hemoglobinopathy Neutropenia ( neutrophil count , &lt; 1,500/mm3 ) Thrombocytopenia ( platelet &lt; 90,000/ mm3 ) Coinfection HBV HIV Chronic alcohol abuse ( daily consumption &gt; 20 g/day ) Autoimmune liver disease Decompensated liver disease ( Child classification B C ) Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Interferon</keyword>
	<keyword>Ribavirin</keyword>
</DOC>